Search

everythinglearnresearchcommunity

for

Search:↓

The antibody created from BCC tissues reacts similarly to both BCC and hair follicles, suggesting BCC may come from hair follicle cells.

Researchers found that certain miRNAs, which affect immune system regulation, are differently expressed in mice with a hair loss condition compared to healthy mice.

Damaging mutations in NFKB2 cause a severe and distinct form of primary immunodeficiency with early-onset and often ACTH-deficiency.

Targeting specific T cells may help treat alopecia areata.

Expanding regulatory T cells may help treat alopecia areata by reducing harmful immune cells.

A new diagnostic model can help better diagnose and understand Alopecia Areata.

Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.

Some diseases can improve the outcomes of other diseases, leading to new treatment possibilities.

Systemic immunotherapies are used for immune-related hair loss but not usually for genetic hair loss, unless the patient has both conditions.

Certain immune markers and vitamin levels could help diagnose alopecia areata.

IFNγ-primed MSC secretomes can improve joint health by reducing inflammation and supporting tissue repair.

Skin's Regulatory T cells are crucial for maintaining skin health and could be targeted to treat immune-related skin diseases and cancer.

IFN-γ and IL-2 are important for T cell activation in hair loss in mice.

Skin issues can indicate immune system problems.

RANKL is crucial for bone health, immune function, and other body processes.

JAK inhibitors show promise for treating various skin disorders effectively and safely.

Certain immune cells in atopic dermatitis skin could be targeted for treatment.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Tissue environment greatly affects the unique epigenetic makeup of regulatory T cells, which could impact autoimmune disease treatment.

Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.

Some cells may slow melanoma growth, a protein could affect skin pigmentation, a gene-silencing method might treat hair defects, skin bacteria changes likely result from eczema, and a defensin protein could help treat multiple sclerosis.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Patients with alopecia areata have higher levels of certain immune markers, suggesting new treatment targets.

Treg cell-based therapies might help treat hair loss from alopecia areata, but more research is needed to confirm safety and effectiveness.

Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.

Belimumab effectively reduces disease activity in lupus patients, regardless of initial serologic status.

ILC1-like cells may contribute to hair loss in alopecia areata.